abrdn plc Buys 190,628 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

abrdn plc grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 179.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 296,772 shares of the medical research company’s stock after buying an additional 190,628 shares during the period. abrdn plc owned 0.08% of Thermo Fisher Scientific worth $157,524,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of TMO. Coppell Advisory Solutions LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $33,000. Live Oak Investment Partners bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $36,000. Tyler Stone Wealth Management bought a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $37,000. Raleigh Capital Management Inc. increased its position in shares of Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares during the last quarter. Finally, Cedar Mountain Advisors LLC increased its position in shares of Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after purchasing an additional 46 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Up 0.6 %

Shares of Thermo Fisher Scientific stock traded up $3.26 during midday trading on Friday, reaching $544.78. 1,738,509 shares of the company’s stock traded hands, compared to its average volume of 1,199,852. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The company has a market cap of $207.95 billion, a PE ratio of 35.26, a price-to-earnings-growth ratio of 2.28 and a beta of 0.80. The stock has a 50 day moving average of $571.27 and a 200-day moving average of $527.45. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.40 earnings per share. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TMO. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Evercore ISI upped their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.